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POINT OF VIEW 
Vision of relevant technologic progress for the 
next two decades 
Thomas J. Fogarty, MD, Stanford, Calif. 
The terms "science" and "technology" are offen 
used interchangeably. In fact, they are quite different. 
Science is the exploration of theory with the purpose 
ofdocumenting the validity or invalidity ofa theoretic 
premise. Technology is the application or implemen- 
tation of proven science for practical purposes. The 
conversion ofscience into technology is influenced by 
multiple factors other than the validity of the science 
(Table I). These additional influences often &ter- 
mine the direction and ultimate acceptance and vi- 
ability of a new technology. When applied to surgical 
therapeutics, old and new technologies can be iden- 
tified and cätegorized as devices, procedures, tech- 
niques, and instrumentation. As illustrated in Täble 
II, there are potentially 36 possible permutations that 
can be created by combining new and old devices, 
procedures, techniques, and instrumentation i to 
new evolutionary technologies. In well-developed 
countries, cardiac and vascular diseases represent 
some of the most common and highly visible disease 
entities that afflict the aged population. As specialists 
who treat these diseases, we will become highly 
influential in creating technologies to address these 
diseases. It is therefore critical that we understand and 
involve ourselvcs in the technologie process. 
A common perception held by both practitioners 
and consumers alike is that new technology equates 
with "increased cost." As we advance technology in 
our specialty, we must consider an overall net eco- 
nomic impact o avoid adding to health care costs. To 
be successful, a new technology should--in fact 
must--demonstrate clinical utility equal or superior 
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to the standard methods that we currently use with- 
out significantly increasing cost. 
It is interesting to note that government itselfhas 
played a role in incrcasing health care costs. Meeting 
the requirements and numerous legislative mandates 
for the purpose of assuring the safety and efficacy of 
new drugs and devices can add approximately 10% to 
50% to total developmental costs. New, less-invasive 
technology, however, represents the most viable 
mechanism for controlling and at times even reducing 
these escalating costs. Table III lists the cost-saving 
benefits that can be realized by using lessqnvasive 
methods. Good technology used appropriately can 
reduce cost; however, good technology used inappro- 
priately and bad technology both serve to increase 
cost. 
It has become increasingly important for physi- 
cians to understand the relationship between cost and 
net economic impact (Table IV). It is a serious error to 
consider only one or two components of the factors 
that contribute to the ner economic impact and 
interpret hat as total cost. For example, the use of 
new instrumentation may be more expensive than the 
instruments hey replace. If, however, that instrumen- 
ration avoids general anesthesia, eliminates critical 
care time, and reduces length of stay, it is quite likely 
to be cost-effective. As surgeons, it is important that 
we recognize that surgical supply costs account for 
approximately 6% ofhospital charges. Materials man- 
agers are sometimes awarded incentives based on the 
supply cost avings they produce. The purchase of an 
unfamiliar or inferior instrument may actually increase 
costs by requiring the use of multiple devices as a 
result of the clinician's unfamiliarity with a new 
product or as a result of the product's inferior quality 
and reliability. Both situations negate any negligible 
cost-saving benefits that were hoped to have been 
gained by using a less expensive, but overall poor, 
substitute for the standard, slightly more expensive 
alternative. In addition, the complications that are 
often associated with use of an unfamiliar instrument, 
suture, or implant may lead to prolonged hospital 
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Fig. 1. Illustration of VasoSeal vascular hemostasis device providing puncturc site sealing by 
application of collagen to outside of femoral artery (photo courtesy of Datascope Corp., 
Montvale, N.J.). 
stays and even increased mortality rates, which further 
increase monetary costs and the patient-related costs 
to life and limb. When these scenarios are carefully 
considered, it becomes clear that obtaining the advice 
ofphysicians in medically related purchase decisions is 
critically important. Without this input significant 
savings are not likely to be realized. 
Health technology advances through the develop- 
ment ofdrugs, procedures, instruments, techniques, 
implants, and services. It is important o appreciate 
that these advancements occur in combination, and 
orten as a result of  one another. For example, trans- 
plantation is possible because of the availability ofim- 
proved techniques and antirejection drugs. 
Less-invasive t chniques fall into two categories-- 
diagnostic and therapeutic. I predict that all less- 
invasive methods will see increasing clinical applica- 
tion and become the standard of care in the future. 
Three areas that deserve particular mention are en- 
abling visualization technologies, access ite manage- 
ment, and controlling the healing response. 
ENABL ING V ISUAL IZAT ION 
TECHNOLOGIES  
The ability to combine diägnostic techniques with 
therapeufic techniques has alrcady occurrcd in the 
ficld of coronary intcrvenfions. This concept will be 
extendcd to the management of pcriphcral vascular 
diseasc. Four visualizafion mcthods that will allow 
diagnosis and therapy to become combincd into one 
effort are illustratcd in Table V. 
Current C-arm fluoroscopy units allow accurate 
diagnosis for the purposcs of sclccfing and implc- 
mcnfing appropriate thcrapeufic int rvcnüons. Fixed 
overhead units are available and offcr some advan- 
tages whcn dcaling with morc advanccd or experi- 
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Fig. 2. Illustration ofAngio-Seal device mode of action used to seal femoral ccess site. After 
absorbable anchor has been inserted into artery lumen (A), it is withdrawn by pulley type of 
absorbable sumre unfil secure at ar terywall. Absorbable collagen sponge isthen deployed outside 
artery, compressing anchor against vessel surface to create a seäl (B). All components are 
absorbed in 60 to 90 days (photo courtesy ofSherwood-Davis & Geck, St. Louis). 
mental techniques. In the majority of routine appli- 
cations of endovascular technology, portable C-arm 
fluoroscopy with road-mapping capability and hard 
copy are safe and cost-effective. These tmits, when 
used in conjunction with other preoperative nonin- 
vasive diagnostic studies, can and should be used to 
corroborate the anatomic diagnosis. Fluoroscopy in- 
dicates to the surgeon whether intervention is re- 
quired and which procedures can be performed; it
also aids in the selection oftools needed to accomplish 
the intervention. As a real-time guide during therapy, 
intraluminal visualization with ultrasonography, an- 
gioscopy, or both will be used with increasing fre- 
quency. Like fluoroscopy, these two visualization 
methods will provide therapeutic guidance, but in 
addition they will document he completeness of 
therapy. An incentive for cost savings will serve to 
accelerate the process of combining diagnostic pro- 
cedures with therapeutic treatment methods. 
ACCESS SITE MANAGEMENT 
The development of percutaneous access by 
Seldinger 1 significantly accelerated the clinical utility 
and acceptance of cardiac catheterization. Sones 2 is 
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Table I. Important influences on technology 
Social 
Economic 
Polifical 
Educational 
Relational 
Governmental 
Other sciences 
Table II. Technology as applied to 
surgical therapeutics 
New Old 
Device Device 
Procedure Procedure 
Technique Technique 
Instrumcntation Instrumentation 
36 possible combinauons. 
Table III. Less-invasive technology 
Decreases cost by: 
1. Decrcasing hospital time 
2. Decreasing time in operafing room 
3. Minimizing anesthesia 
4. Minimizing extent ofprocerdures 
a) Decreasing tissuc manipulation 
b) Smallcr and fewer incisions 
5. Minimizing recovery time 
credited with documenting the safety of coronary 
visualization. In this procedure he gaincd access via 
direct cutdown on the brachial artery. Later, Judkins 3 
popularized the femoral percutaneous approach for 
intracoronary visualization. This approach was made 
possible by the introduction of specialized catheters 
that could be preformed in various hapes. With the 
development of techniques for coronary therapeutic 
interventions, catheter systems with a larger diameter 
are needed. Many of these advanced therapeufic 
interventions are associated with the use of antico- 
agulant, antiplatelet, and fibrinolytic drugs. Anti- 
platelet and fibrinolytic drugs have resulted in a 
significant increase in the frequency and magnitude of 
femoral puncture site complications. 
The standard routine for puncture site manage- 
ment typically involves direct compression over the 
puncture site during prolonged periods of bed rest 
and immobilization. Frequent observation of the 
access ite is required by trained personnel. Compli- 
cations associated with puncture site management 
according to the method described to achieve access 
site hemostasis are responsible for more than 15% of 
the costs associated with advanced therapeutic nter- 
ventions. 
Table IV. Procedure conomics 
Net economic impact 
Procedure time 
Hospital stay 
Labor cost 
Surveillance 
Supply cost 
Recovery time 
Aftercare 
Decreased cost, increased care 
Pain and suffcring 
Table V. Enabling visualization technologies 
for endovascular p ocedures 
C-arm fluoroscopy--flow 
Intraluminal ultrasonography--wall morphology 
Angioscopy--surface anatomy 
NMR and CT--relational anatomy 
NMR, Nuclear magnetic resonance; CT, computed tomography. 
Complications related to femoral artery access 
sites include hematoma, arteriovenous fistula, re- 
bleeding, pseudoaneurysm, and local and systemic 
infection. In situ thrombosis, distal embolization, 
anemia requiring transfusion, and cansalgia re addi- 
tional significant untoward events. Recently devel- 
oped access ite closure devices appear to eliminate 
many of the problems and complications associated 
with percutaneous punctures and offer an optimistic 
outlook for advancing percutaneous procedures in 
the future. 
The VasoSeal (Datascope Corp., Montvale, N.J.) 
and the Angio-Seal (Sherwood-Davis & Geck, St. 
Louis) are two collagen closure devices used for 
puncture site management that have recently under- 
gone clinical trials. The technology used in these 
devices is iUustrated in Figs. 1 and 2, respectively. 
These devices are appropriate for specific clinical 
applications, pecifically the closure ofpercutaneous 
angiography access ites. Both devices use collagen to 
seal within or on either side of the puncture site. 
Despite offering a positive advantage tomanaging the 
percutaneous access ite, the need for prolonged bed 
rest and immobilizafion after the procedure is not 
totally eliminated. 
Although standard surgical repair ofpuncture site 
complications i effective, it is not routinely per- 
formed because surgical closure xposes patients to an 
unnecessary operation and is expensive. 
Devices that accomplish percutaneous closure 
with a suture technique have been developed. 4 These 
devices are capable ofclosing puncture sites ranging in 
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Fig. 3. Illustration of Prostar percutaneous vascular surgical closure device. A, Sheath loaded 
with four needles carrying sumres is placed into artery; B, needles are deployed through artery 
wall as device handle is pulled upward; C, square knots are tied in each suture and delivered to 
artery surfaee with knot pusher. Complete hemostasis is achieved with percutaneous approach 
(photo courtesy of Perclose, Inc., Menlo Park, Calif.). 
size from 5F to l lF .  Prostar (Perclose, Inc., Menlo 
Park, Calif.) is an instrument designed to effectively 
close punctures made by the larger 9F through l l F  
sheaths. The instrument is exchanged for the femoral 
sheath at the completion of the intervention. An 
illustration of the device in use is shown in Fig. 3. 
Additional larger sizes that offer the potential for the 
percutaneous introduction of steht grafts in some 
circumstances are under evaluation. There is an ob- 
vious limit to the size ofa percutaneous puncture site 
that can be closed with the percutaneous closure 
technique. Percutaneous suture closure of arterial 
puncture sites has undergone clinical evaluation and 
has proved to be extremely effective. To date, expe- 
rience with this device, although limited, has been 
very positive. The approach allows immcdiate patient 
mobilization in the presence of continued uninter- 
rupted anticoagulant therapy. Shortened hospital re- 
cuperations have resulted, and early restudy through 
the same limb access itc is possible. It is likely that 
with additional larger-sized instruments and an in- 
creased awareness of the improved puncture site 
JOURNAL OF VASCULAR SURGERY 
296 Fogarty August 1996 
management techniques, the applications ofpercuta- 
neous mediated procedures for both occlusive and 
aneurysmal disease will expand. 
CONTROL OF THE HEALING RESPONSE 
An inability to control the healing process is 
responsible for most occlusive failures seen in revas- 
cularization procedures. Early failures that occur 
before 6 months are often caused either by an 
inadequate initial procedtrre, by thrombosis at the 
injury site, or both. Failures beyond 6 months are the 
result of a healing response at the area of vascular 
tissue injury. An excessive fibroblastic response at 
these sites results in narrowing and ultimate occlu- 
sion. Smaller vessels (< 5 mm in diameter) are parUcu- 
larly susceptible tothese types oflate failures. Devices 
are being developed that are designed to provide local 
deposition of pharmacologic agents to the arterial 
wall, residual arterial wall, and surrounding tissue 
with catheter techniques. The slow release of thera- 
peutic compounds developed to inhibit the healing 
process is currently being evaluated clinically. The list 
ofinhibitory agents includes antiplatelet compounds, 
antithrombotic drugs, and antihealing drugs. It is 
likely that in the future these drug entities will be used 
at all anastomotic sites and areas of endoluminal 
disease manipulated by catheter systems. 
CONCLUSION 
When envisioning the technologic process, we 
must "think young" and consider the impossible. 
This mindset is best achieved in an environment 
where innovators consider the unachievable as being 
possible. If technology is to be advanced, we must 
make every effort to allow new ideas to be nurtured, 
refined, clinically tested for safety and efficacy, and 
evaluated inall aspects. This critical evaluation should 
also carefully consider the technology's net economic 
impact. I believe that in the future our vascular 
specialty will wimess a decided shift toward less- 
invasive technology in our surgical approaches. Mini- 
mally invasive catheter-based interventions offer a real 
potential to provide equal or superior clinical out- 
comes at reduced costs. 
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